Proton Pump Inhibitors and Risk of Dementia: A Hypothesis Generated but Not Adequately Tested

American Journal of Alzheimer’s Disease &Other Dementias®, Volume 36, Issue , January-December 2021.
We reviewed the evidence on proton pump inhibitors (PPIs) and dementia. PPIs are among the most widely utilized drugs in the world. Dementia affects roughly 5% of the population of the United States (US) and world aged 60 years and older. With respect to PPIs and dementia, basic research has suggested plausible mechanisms but descriptive and analytic epidemiological studies are not inconsistent. In addition, a single large-scale randomized trial showed no association. When the evidence is incomplete, it is appropriate for clinicians and researchers to remain uncertain. Regulatory or public health authorities sometimes need to make real-world decisions based on real-world data. When the evidence is complete, then the most rational judgments for individual patients the health of the general public are possible At present, the evidence on PPIs and dementia suggests more reassurance than alarm. Further large-scale randomized evidence is necessary to do so.Proton Pump Inhibitors and Risk of Dementia: A Hypothesis Generated but Not Adequately TestedProton Pump Inhibitors and Risk of Dementia: A Hypothesis Generated but Not Adequately TestedAlzheimers{$excerpt:n}